MakeMyTrip Q1 Adjusted Earnings, Revenue Rise-March 2024-www.financetom.com

MakeMyTrip Q1 Adjusted Earnings, Revenue Rise

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

MakeMyTrip Q1 Adjusted Earnings, Revenue Rise

Jul 23, 2024 5:19 AM

07:50 AM EDT, 07/23/2024 (MT Newswires) -- MakeMyTrip ( MMYT ) reported fiscal Q1 2025 adjusted earnings Tuesday of $0.39 per diluted share, up from $0.30 a year earlier.

Two analysts polled by Capital IQ expected $0.36.

Revenue for the quarter ended June 30 was $254.52 million, up from $196.73 million a year earlier.

Analysts surveyed by Capital IQ expected $242.19 million.

MakeMyTrip ( MMYT ) shares rose 3.8% in pre-market activity.

Price: 93.00, Change: +3.38, Percent Change: +3.77

Previous page： Xencor Names Bart Cornelissen as Chief Financial Officer Next page： Banxa Holdings Up More Than 2% After Reporting "Positive" Operating Cashflow In February, and Flagging Improvement in March, April

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Xencor Names Bart Cornelissen as Chief Financial Officer

Apr 9, 2024

10:27 AM EDT, 04/09/2024 (MT Newswires) -- Xencor ( XNCR ) said Tuesday it has appointed Bart Cornelissen as chief financial officer. Cornelissen most recently served as vice president of corporate finance at Seagen. Xencor ( XNCR ) shares were up 2.7% in recent trading. Price: 22.08, Change: +0.58, Percent Change: +2.67 ...

Banxa Holdings Up More Than 2% After Reporting "Positive" Operating Cashflow In February, and Flagging Improvement in March, April

Apr 9, 2024

10:23 AM EDT, 04/09/2024 (MT Newswires) -- Banxa Holdings ( BNXAF ) was up more than 2% at last look on Tuesday after saying that it achieved sustainable positive operating cash flow in February and sees that improving in the coming months. It's encouraging to see that March and April are looking even better, said Banxa ( BNXAF ) Chairman...

Novartis to cut 680 jobs in product development

Apr 9, 2024

ZURICH (Reuters) - Novartis is to cut up to 680 jobs in its development organisation, which helps bring its drugs to market, the Swiss pharmaceuticals company said on Tuesday. Around 440 jobs will go in Switzerland and up to 240 in the United States over the next two to three years, the Basel-based company said. The job eliminations are separate...

Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday?

Apr 9, 2024

On Monday, Vincerx Pharma Inc ( VINC ) presented preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research Annual Meeting 2024. VNC-236-101 is a Phase 1 dose-escalation study with monotherapy VIP236 for metastatic tumor patients who have exhausted all standard therapy options. Fifteen patients have been dosed to date on the once-every-three-weeks (Q3W) schedule:...